

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/463,098

DATE: 03/29/2001
TIME: 16:01:14

Input Set : A:\Nicosia.APP.txt
Output Set: N:\CRF3\03292001\I463098.raw

4 <110> APPLICANT: Nicosia, Alfredo
5 Lahm, Armin
6 Tramontano, Anna
7 Cortese, Riccardo
9 <120> TITLE OF INVENTION: Mimotopes of hypervariable region 1 of the E2
10 glycoprotein of HCV and uses thereof
12 <130> FILE REFERENCE: Mewburn
14 <140> CURRENT APPLICATION NUMBER: US 09/463,098
C--> 15 <141> CURRENT FILING DATE: 2000-05-05
17 <150> PRIOR APPLICATION NUMBER: PCT/EP99/03344
18 <151> PRIOR FILING DATE: 1999-05-14
20 <150> PRIOR APPLICATION NUMBER: GB 9810756.8
21 <151> PRIOR FILING DATE: 1998-05-19
23 <160> NUMBER OF SEQ ID NOS: 199
25 <170> SOFTWARE: PatentIn Ver. 2.1
27 <210> SEQ ID NO: 1
28 <211> LENGTH: 27
29 <212> TYPE: PRT
30 <213> ORGANISM: Artificial Sequence
32 <220> FEATURE:
33 <221> NAME/KEY: SITE
34 <222> LOCATION: (1)
35 <223> OTHER INFORMATION: Xaa is Gln or Thr
37 <220> FEATURE:
38 <221> NAME/KEY: SITE
39 <222> LOCATION: (3)
40 <223> OTHER INFORMATION: Xaa is His, Thr or Arg
42 <220> FEATURE:
43 <221> NAME/KEY: SITE
44 <222> LOCATION: (4)
45 <223> OTHER INFORMATION: Xaa is Val or Thr
47 <220> FEATURE:
48 <221> NAME/KEY: SITE
49 <222> LOCATION: (5)
50 <223> OTHER INFORMATION: Xaa is Thr or Val
52 <220> FEATURE:
53 <221> NAME/KEY: SITE
54 <222> LOCATION: (8)
55 <223> OTHER INFORMATION: Xaa is Ser, Val or Gln
57 <220> FEATURE:
58 <221> NAME/KEY: SITE
59 <222> LOCATION: (9)
60 <223> OTHER INFORMATION: Xaa is Ala, Gln or Val
64 <220> FEATURE:
65 <221> NAME/KEY: SITE
66 <222> LOCATION: (10)
67 <223> OTHER INFORMATION: Xaa is Ala, Gly or Ser

1627
RECEIVED
APR 06 2001
TECH CENTER 1600/2900

ENTERED

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/463,098

DATE: 03/29/2001

TIME: 16:01:14

Input Set : A:\Nicosia.APP.txt

Output Set: N:\CRF3\03292001\I463098.raw

69 <220> FEATURE:
70 <221> NAME/KEY: SITE
71 <222> LOCATION: (11)
72 <223> OTHER INFORMATION: Xaa is Arg or His
74 <220> FEATURE:
75 <221> NAME/KEY: SITE
76 <222> LOCATION: (12)
77 <223> OTHER INFORMATION: Xaa is Thr, Ala or Gln
79 <220> FEATURE:
80 <221> NAME/KEY: SITE
81 <222> LOCATION: (13)
82 <223> OTHER INFORMATION: Xaa is Thr, Ala or Val
84 <220> FEATURE:
85 <221> NAME/KEY: SITE
86 <222> LOCATION: (14)
87 <223> OTHER INFORMATION: Xaa is Ser, His or Arg
89 <220> FEATURE:
90 <221> NAME/KEY: SITE
91 <222> LOCATION: (15)
92 <223> OTHER INFORMATION: Xaa is Gly, Ser or Arg
94 <220> FEATURE:
95 <221> NAME/KEY: SITE
96 <222> LOCATION: (17)
97 <223> OTHER INFORMATION: Xaa is Thr or Val
99 <220> FEATURE:
100 <221> NAME/KEY: SITE
101 <222> LOCATION: (18)
102 <223> OTHER INFORMATION: Xaa is Ser, Gly or Arg
104 <220> FEATURE:
105 <221> NAME/KEY: SITE
106 <222> LOCATION: (21)
107 <223> OTHER INFORMATION: Xaa is Ser or Arg
109 <220> FEATURE:
110 <221> NAME/KEY: SITE
111 <222> LOCATION: (22)
112 <223> OTHER INFORMATION: Xaa is Pro, Leu, Ser or Gln
114 <220> FEATURE:
115 <221> NAME/KEY: SITE
116 <222> LOCATION: (24)
117 <223> OTHER INFORMATION: Xaa is Ala, Pro or Ser
119 <220> FEATURE:
120 <221> NAME/KEY: SITE
121 <222> LOCATION: (25)
122 <223> OTHER INFORMATION: Xaa is Ser, Lys or Gln
127 <220> FEATURE:
128 <221> NAME/KEY: SITE
129 <222> LOCATION: (27)
130 <223> OTHER INFORMATION: Xaa is Asn or Lys
132 <220> FEATURE:

RAW SEQUENCE LISTING
 PATENT APPLICATION: US/09/463,098

DATE: 03/29/2001
 TIME: 16:01:14

Input Set : A:\Nicosia.APP.txt
 Output Set: N:\CRF3\03292001\I463098.raw

133 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 134 peptide

136 <400> SEQUENCE: 1

137 Xaa Thr Xaa Xaa Xaa Gly Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu

138 1 5 10 15

140 Xaa Xaa Leu Phe Xaa Xaa Gly Xaa Xaa Gln Xaa

141 20 25

144 <210> SEQ ID NO: 2

145 <211> LENGTH: 27

146 <212> TYPE: PRT

147 <213> ORGANISM: Artificial Sequence

149 <220> FEATURE:

150 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 151 peptide

153 <400> SEQUENCE: 2

154 Gln Thr His Thr Val Gly Gly Val Gln Gly Arg Gln Ala His Ser Leu

155 1 5 10 15

157 Thr Ser Leu Phe Ser Pro Gly Ala Ser Gln Asn

158 20 25

161 <210> SEQ ID NO: 3

162 <211> LENGTH: 27

163 <212> TYPE: PRT

164 <213> ORGANISM: Artificial Sequence

166 <220> FEATURE:

167 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 168 peptide

170 <400> SEQUENCE: 3

171 Gln Thr Thr Thr Thr Gly Gly Gln Val Ser His Ala Thr His Gly Leu

172 1 5 10 15

174 Thr Gly Leu Phe Ser Leu Gly Pro Gln Gln Lys

175 20 25

178 <210> SEQ ID NO: 4

179 <211> LENGTH: 27

180 <212> TYPE: PRT

181 <213> ORGANISM: Artificial Sequence

183 <220> FEATURE:

184 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 185 peptide

187 <400> SEQUENCE: 4

188 Gln Thr His Thr Thr Gly Gly Ser Ala Ser His Gln Ala Ser Gly Leu

189 1 5 10 15

191 Thr Arg Leu Phe Ser Gln Gly Pro Ser Gln Asn

192 20 25

195 <210> SEQ ID NO: 5

196 <211> LENGTH: 27

197 <212> TYPE: PRT

198 <213> ORGANISM: Artificial Sequence

200 <220> FEATURE:

201 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/463,098

DATE: 03/29/2001

TIME: 16:01:14

Input Set : A:\Nicosia.APP.txt

Output Set: N:\CRF3\03292001\I463098.raw

```

202      peptide
204 <400> SEQUENCE: 5
205 Gln Thr His Val Val Gly Gly Gln Gln Gly Arg Gln Val Ser Ser Leu
206   1              5              10              15
208 Val Ser Leu Phe Ser Pro Gly Ala Ser Gln Lys
209           20           25
212 <210> SEQ ID NO: 6
213 <211> LENGTH: 27
214 <212> TYPE: PRT
215 <213> ORGANISM: Artificial Sequence
217 <220> FEATURE:
218 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
219      peptide
221 <400> SEQUENCE: 6
222 Thr Thr His Thr Val Gly Gly Ser Val Ala Arg Gln Val His Ser Leu
223   1              5              10              15
225 Thr Gly Leu Phe Ser Pro Gly Pro Gln Gln Lys
226           20           25
229 <210> SEQ ID NO: 7
230 <211> LENGTH: 27
231 <212> TYPE: PRT
232 <213> ORGANISM: Artificial Sequence
234 <220> FEATURE:
235 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
236      peptide
238 <400> SEQUENCE: 7
239 Gln Thr His Thr Val Gly Gly Ser Gln Ala His Ala Ala His Ser Leu
240   1              5              10              15
242 Thr Arg Leu Phe Ser Pro Gly Ser Ser Gln Asn
243           20           25
246 <210> SEQ ID NO: 8
247 <211> LENGTH: 27
248 <212> TYPE: PRT
249 <213> ORGANISM: Artificial Sequence
251 <220> FEATURE:
252 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
253      peptide
255 <400> SEQUENCE: 8
256 Gln Thr Thr Val Val Gly Gly Ser Gln Ala Arg Ala Ala His Gly Leu
257   1              5              10              15
259 Val Ser Leu Phe Ser Leu Gly Ser Lys Gln Asn
260           20           25
263 <210> SEQ ID NO: 9
264 <211> LENGTH: 27
265 <212> TYPE: PRT
266 <213> ORGANISM: Artificial Sequence
268 <220> FEATURE:
269 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
270      peptide

```

RAW SEQUENCE LISTING DATE: 03/29/2001
 PATENT APPLICATION: US/09/463,098 TIME: 16:01:14

Input Set : A:\Nicosia.APP.txt
 Output Set: N:\CRF3\03292001\I463098.raw

```

272 <400> SEQUENCE: 9
273 Gln Thr His Val Val Gly Gly Val Gln Gly Arg Gln Thr Ser Gly Leu
274   1               5               10               15
276 Val Gly Leu Phe Ser Pro Gly Ser Lys Gln Asn
277   20               25
280 <210> SEQ ID NO: 10
281 <211> LENGTH: 27
282 <212> TYPE: PRT
283 <213> ORGANISM: Artificial Sequence
285 <220> FEATURE:
286 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
287     peptide
289 <400> SEQUENCE: 10
290 Gln Thr Thr Val Val Gly Gly Ser Gln Ser His Thr Val Arg Gly Leu
291   1               5               10               15
293 Thr Ser Leu Phe Ser Pro Gly Ala Ser Gln Asn
294   20               25
297 <210> SEQ ID NO: 11
298 <211> LENGTH: 27
299 <212> TYPE: PRT
300 <213> ORGANISM: Artificial Sequence
302 <220> FEATURE:
303 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
304     peptide
306 <400> SEQUENCE: 11
307 Thr Thr Thr Thr Thr Gly Gly Gln Ala Gly His Gln Ala His Ser Leu
308   1               5               10               15
310 Thr Ser Leu Phe Ser Pro Gly Ala Ser Gln Lys
311   20               25
314 <210> SEQ ID NO: 12
315 <211> LENGTH: 27
316 <212> TYPE: PRT
317 <213> ORGANISM: Artificial Sequence
319 <220> FEATURE:
320 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
321     peptide
323 <400> SEQUENCE: 12
324 Gln Thr His Val Val Gly Gly Val Gln Ser His Gln Thr Ser Gly Leu
325   1               5               10               15
327 Thr Ser Leu Phe Ser Pro Gly Ala Ser Gln Lys
328   20               25
331 <210> SEQ ID NO: 13
332 <211> LENGTH: 27
333 <212> TYPE: PRT
334 <213> ORGANISM: Artificial Sequence
336 <220> FEATURE:
337 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
338     peptide
340 <400> SEQUENCE: 13

```

PI

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

VERIFICATION SUMMARY

DATE: 03/29/2001

PATENT APPLICATION: US/09/463,098

TIME: 16:01:15

Input Set : A:\Nicosia.APP.txt

Output Set: N:\CRF3\03292001\I463098.raw

L:15 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:137 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:140 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:574 M:283 W: Missing Blank Line separator, <220> field identifier
L:808 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:39
L:811 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:39
L:955 M:283 W: Missing Blank Line separator, <220> field identifier
L:1722 M:283 W: Missing Blank Line separator, <220> field identifier
L:2746 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:148
L:2749 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:148
L:3419 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:198
L:3463 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:199